Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
44
FONR Quote, Financials, Valuation and Earnings
Last price:
$18.62
Seasonality move
:
3.79%
Day range:
$18.60 - $18.63
52-week range:
$12.00 - $18.86
Dividend yield:
0%
P/E ratio:
16.82x
P/S ratio:
1.13x
P/B ratio:
0.67x
Volume:
71.3K
Avg. volume:
118.3K
1-year change:
19.22%
Market cap:
$117.2M
Revenue:
$104.4M
EPS (TTM):
$1.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.23 | -80.82% | -75.61% | $7.00 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$134.5M | $0.40 | 14.28% | 278.39% | $47.67 |
|
XGN
Exagen, Inc.
|
$16.9M | -$0.18 | 13.89% | -20.87% | $14.71 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
$18.61 | -- | $117.2M | 16.82x | $0.00 | 0% | 1.13x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$6.52 | $7.00 | $186.9M | -- | $0.00 | 0% | 39.67x |
|
PRPH
ProPhase Labs, Inc.
|
$0.36 | $13.80 | $1.5M | -- | $0.00 | 0% | 0.25x |
|
VCYT
Veracyte, Inc.
|
$42.27 | $47.67 | $3.3B | 111.35x | $0.00 | 0% | 6.79x |
|
XGN
Exagen, Inc.
|
$4.60 | $14.71 | $104.3M | -- | $0.00 | 0% | 1.46x |
|
XWEL
XWELL, Inc.
|
$0.35 | -- | $2M | -- | $0.00 | 0% | 0.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.710 | 3.29% | 2.57x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.343 | 11.39% | 3.63x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
FONAR Corp. vs. Competitors
-
Which has Higher Returns FONR or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -4174.62%. FONAR Corp.'s return on equity of 5.84% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About FONR or IMDX?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 7.36%. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than FONAR Corp., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is FONR or IMDX More Risky?
FONAR Corp. has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.885%.
-
Which is a Better Dividend Stock FONR or IMDX?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or IMDX?
FONAR Corp. quarterly revenues are $26M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. FONAR Corp.'s net income of $2.7M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, FONAR Corp.'s price-to-earnings ratio is 16.82x while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 1.13x versus 39.67x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.1.13x 16.82x $26M $2.7M IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M
-
Which has Higher Returns FONR or PRPH?
ProPhase Labs, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -774.52%. FONAR Corp.'s return on equity of 5.84% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About FONR or PRPH?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 37958.47%. Given that ProPhase Labs, Inc. has higher upside potential than FONAR Corp., analysts believe ProPhase Labs, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 PRPHProPhase Labs, Inc.0 0 0 -
Is FONR or PRPH More Risky?
FONAR Corp. has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock FONR or PRPH?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or PRPH?
FONAR Corp. quarterly revenues are $26M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. FONAR Corp.'s net income of $2.7M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, FONAR Corp.'s price-to-earnings ratio is 16.82x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 1.13x versus 0.25x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.1.13x 16.82x $26M $2.7M PRPHProPhase Labs, Inc.0.25x -- $883K -$6.8M
-
Which has Higher Returns FONR or VCYT?
Veracyte, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of 14.51%. FONAR Corp.'s return on equity of 5.84% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About FONR or VCYT?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 12.77%. Given that Veracyte, Inc. has higher upside potential than FONAR Corp., analysts believe Veracyte, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is FONR or VCYT More Risky?
FONAR Corp. has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock FONR or VCYT?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or VCYT?
FONAR Corp. quarterly revenues are $26M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. FONAR Corp.'s net income of $2.7M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, FONAR Corp.'s price-to-earnings ratio is 16.82x while Veracyte, Inc.'s PE ratio is 111.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 1.13x versus 6.79x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.1.13x 16.82x $26M $2.7M VCYTVeracyte, Inc.6.79x 111.35x $131.9M $19.1M
-
Which has Higher Returns FONR or XGN?
Exagen, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -41.1%. FONAR Corp.'s return on equity of 5.84% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About FONR or XGN?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Exagen, Inc. has an analysts' consensus of $14.71 which suggests that it could grow by 219.88%. Given that Exagen, Inc. has higher upside potential than FONAR Corp., analysts believe Exagen, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 XGNExagen, Inc.8 0 0 -
Is FONR or XGN More Risky?
FONAR Corp. has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.324%.
-
Which is a Better Dividend Stock FONR or XGN?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or XGN?
FONAR Corp. quarterly revenues are $26M, which are larger than Exagen, Inc. quarterly revenues of $17.2M. FONAR Corp.'s net income of $2.7M is higher than Exagen, Inc.'s net income of -$7.1M. Notably, FONAR Corp.'s price-to-earnings ratio is 16.82x while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 1.13x versus 1.46x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.1.13x 16.82x $26M $2.7M XGNExagen, Inc.1.46x -- $17.2M -$7.1M
-
Which has Higher Returns FONR or XWEL?
XWELL, Inc. has a net margin of 10.25% compared to FONAR Corp.'s net margin of -2.87%. FONAR Corp.'s return on equity of 5.84% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital FONRFONAR Corp.40.11% $0.34 $201.3M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About FONR or XWEL?
FONAR Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1927.81%. Given that XWELL, Inc. has higher upside potential than FONAR Corp., analysts believe XWELL, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings FONRFONAR Corp.0 0 0 XWELXWELL, Inc.0 0 0 -
Is FONR or XWEL More Risky?
FONAR Corp. has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.
-
Which is a Better Dividend Stock FONR or XWEL?
FONAR Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FONAR Corp. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FONR or XWEL?
FONAR Corp. quarterly revenues are $26M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. FONAR Corp.'s net income of $2.7M is higher than XWELL, Inc.'s net income of -$211K. Notably, FONAR Corp.'s price-to-earnings ratio is 16.82x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FONAR Corp. is 1.13x versus 0.06x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FONRFONAR Corp.1.13x 16.82x $26M $2.7M XWELXWELL, Inc.0.06x -- $7.3M -$211K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 24
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
64
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Sell
19
APGE alert for Jan 24
Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.
